In May, a handful of new biopharmaceutical companies came onto the scene; one of which was Portola Pharmaceuticals (NASDAQ: PTLA). Portola's initial pricing was at $14.50 per common share with a market cap around $470 million. Since the IPO, Portola's stock has appreciated to $20.05; proving a nice 38.3% gain in roughly three weeks! With such a remarkable return in such a short amount of time, a few questions come to mind in regards to the current valuation.
The basis of this article is to provide:
1. A brief overview of the company
2. Detailed analysis of the lead products: Betrixaban and PRT4445
3. Quick overview of pipeline
4. Opinionated conclusions in regard to the current valuation
Brief Introduction... ...